Next Article in Journal
Diagnostic and Prognostic Significance of Carboxypeptidase A4 (CPA4) in Breast Cancer
Next Article in Special Issue
New Approaches for the Discovery of Pharmacologically-Active Natural Compounds
Previous Article in Journal
Cellular and Immunohistochemical Changes in Anaphylactic Shock Induced in the Ovalbumin-Sensitized Wistar Rat Model
Previous Article in Special Issue
Formulations of Curcumin Nanoparticles for Brain Diseases
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Biomolecules 2019, 9(3), 102;

Analysis of Flavonoids Bioactivity for Cholestatic Liver Disease: Systematic Literature Search and Experimental Approaches

Instituto de Medicina Molecular y Ciencias Avanzadas, Mexico City 01900, Mexico
Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, MOR 62209, Mexico
Instituto Nacional de Neurología y Neurocirugía, Mexico City 14269, Mexico
Unidad de Investigación Médica en Bioquímica, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, IMSS, México City 06720, Mexico
Unidad de Biomedicina, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico
Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, México
Authors to whom correspondence should be addressed.
Received: 2 December 2018 / Revised: 7 March 2019 / Accepted: 7 March 2019 / Published: 14 March 2019
PDF [4470 KB, uploaded 14 March 2019]


Flavonoids are naturally occurring compounds that show health benefits on the liver. However, there is little investigation about identification and evaluation of new flavonoid-containing drugs for cholestatic liver disease, one of the most common liver illnesses. We aimed to a systematic search regarding efficacy of flavonoids for treatment of cholestatic liver disease, and then evaluate naringenin (NG) as representative flavonoid in an obstructive cholestasis model. We searched for information of experimental and clinical studies in four major databases without time and language limits. Intervention was defined as any flavonoid derivate compared with other flavonoid, placebo, or without comparator. In addition, we evaluated NG on a bile duct-ligated model in order to contribute evidence of its actions. Eleven experimental reports that support the efficacy of flavonoids in cholestatic liver disease were identified. However, there was no homogeneity in efficacy endpoints evaluated and methodology. On the other hand, NG showed beneficial effects by improving specific metabolic (cholesterol and lipoproteins) and liver damage (bilirubin and alkaline phosphatase) biomarkers. The review lacks homogeneous evidence about efficacy of flavonoids in experimental settings, and is susceptible to risk for bias. NG only showed improvements in specific disease biomarkers. More investigation is still needed to determine its potential for drug development. View Full-Text
Keywords: flavonoids; systematic review; cholestasis flavonoids; systematic review; cholestasis

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Sánchez-Salgado, J.C.; Estrada-Soto, S.; García-Jiménez, S.; Montes, S.; Gómez-Zamudio, J.; Villalobos-Molina, R. Analysis of Flavonoids Bioactivity for Cholestatic Liver Disease: Systematic Literature Search and Experimental Approaches. Biomolecules 2019, 9, 102.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomolecules EISSN 2218-273X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top